+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 6Months +
All Genders
ID07845825

Channeling Hope Trial 1 An Open-label Study Evaluating Safety, Tolerability, and Pharmacokinetics of Chronic Aprepitant Use in Individuals with CLIFAHDD

Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-10-05

5

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

This research is focused on Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay CLIFAHDD, a very rare and severe neurodevelopmental disorder that begins in early infancy. Currently, there are no drug treatments available for this condition, which involves symptoms such as delayed development, movement disorders, seizures, and breathing problems. The study aims to evaluate the safety and effects of aprepitant, a drug already approved for nausea related to chemotherapy, in people with CLIFAHDD. This is a Phase 1 clinical trial conducted by the University of Texas Health Science Center at San Antonio. Participants will receive oral aprepitant starting at a dose of 1mgkg up to 40mg for the first 4 weeks, then the dose will increase to 2mgkg up to 80mg for weeks 5 to 8, and finally to 3mgkg up to 125mg for weeks 9 to 12. The study includes a dose escalation design with careful monitoring. Participants will travel to the study center for baseline assessments and pharmacokinetic PK studies, including detailed blood sampling over 72 hours after the first dose. Subsequent PK and safety assessments will be done at the end of each 4-week cycle to guide dose increases. During the study, participants will be closely monitored for safety, tolerability, and drug levels. Clinical outcomes and potential biomarkers related to the disease will also be evaluated. The total study duration is about 8 months, including a 90-day lead-in period before starting the drug and a 21-day follow-up after treatment ends. Safety monitoring will continue remotely for 3 weeks after the last dose. The main outcomes measured are adverse events, dose-limiting toxicities, and maximum dose reached.

CONDITIONS

Brief Title

Aprepitant for the Treatment of CLIFAHDD

Research Team

M

Megan Iammarino, DPT

R

Randee Kent-Baron

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here